Etonitazene Stats & Data

Etonitazene is an ultra-potent benzimidazole opioid; class reports place it at roughly 1,000–1,500× morphine potency in animals, implying microgram-level human activity and an extreme overdose risk from tiny mismeasurements. It has appeared in the unregulated supply, sometimes sold as or alongside other opioids or as counterfeit pills; related etonitazene analogs have been detected in tablets marked as oxycodone. Nitazenes are often below the detection limits of common onsite spectrometers (e.g., FTIR at ~5% w/w), and available nitazene test strips may not reliably detect all analogs; lab-based drug checking is recommended. Mixed-depressant use (benzodiazepines, alcohol, GHB/GBL, Z-drugs, barbiturates) greatly increases the risk of rapid, profound respiratory depression and death. Co-use with gabapentinoids (gabapentin/pregabalin) is epidemiologically associated with higher opioid-related mortality and should be avoided. In suspected opioid poisoning, naloxone should be administered promptly; multiple repeat doses and prolonged monitoring can be required because nitazenes may outlast naloxone, with risk of renarcotization after initial reversal. Fentanyl test strips detect fentanyl-class opioids; they do not identify which nitazene is present and onsite tools can miss nitazenes—negative results do not guarantee safety. Never “eyeball” or guess amounts; microgram-active materials require precision handling, and insufflation or injection sharply elevates risk. Avoid using alone; ensure bystanders can recognize opioid overdose (unresponsiveness, slow or stopped breathing, pinpoint pupils) and can administer naloxone while calling emergency services.